Fenwick represented Prelude Therapeutics Inc. (NASDAQ: PRLD), a clinical-stage precision oncology company, in its initial public offering of 9,573,750 shares of its common stock at a price to the public of $19.00 per share.
The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses.
Morgan Stanley, Goldman Sachs & Co. LLC and BofA Securities acted as joint book-running managers for the offering.
More information about the offering can be obtained from Prelude Therapeutics’ announcement.
The Fenwick transaction team included corporate partners Robert Freedman and Effie Toshav and associates Julia Forbess, Alice Lin, Andrew Murphy, Emily Yi, Mitchell Duncombe and John Clancy; as well as executive compensation and employee benefits partner Matthew Cantor.